文献速递核素与放射性配体治疗

[177Lu]Lu标记的抗claudin-18.2抗体在胃癌小鼠异种移植模型中显示放射免疫治疗潜力

[177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-12-08

本研究将CLDN18.2抗体TST001经DOTA偶联并用177Lu标记,在胃癌细胞和小鼠异种移植模型中评估其靶向性、疗效与毒性。结果显示[177Lu]Lu-TST001标记率高、稳定性好,5.55 MBq与11.10 MBq剂量均显著抑制CLDN18.2阳性肿瘤生长且11.10 MBq疗效更优,高剂量下未见明显短期器官毒性或血液、肝脏毒性。

要点

  • [177Lu]Lu-TST001放射化学纯度为99.17%±0.32,7天后稳定性≥94%。
  • 5.55 MBq与11.10 MBq剂量均较生理盐水对照组显著抑制肿瘤生长,11.10 MBq疗效更优。
  • 高剂量治疗下心、脾、胃等重要器官未见明显短期毒性,无明显血液或肝脏毒性。

核心结论

  • 临床前研究中,[177Lu]Lu-TST001显示出显著抗肿瘤疗效且毒性可接受,具有较强临床转化潜力,为包括胃癌在内的CLDN18.2过表达肿瘤提供新的有前景的治疗选择。

研究设计与样本

  • 将CLDN18.2抗体TST001(由Transcenta提供)与DOTA偶联并用放射性核素177Lu标记,通过细胞摄取、显像和生物分布实验评估特异性和靶向能力。
  • 在BGC823CLDN18.2与AGSCLDN18.2小鼠模型中验证[177Lu]Lu-TST001对CLDN18.2表达肿瘤的疗效,并通过H&E染色和血液样本检测评估毒性。

主要发现

  • [177Lu]Lu-TST001的放射化学纯度为99.17%±0.32,比活度为18.50±1.27 MBq/nmol,7天后稳定性≥94%。
  • 在胃癌小鼠模型的CLDN18.2阳性异种移植瘤中,[177Lu]Lu-TST001表现出特异性且高的肿瘤摄取。
  • BGC823CLDN18.2与AGSCLDN18.2荷瘤小鼠生存研究显示,低剂量5.55 MBq和高剂量11.10 MBq的[177Lu]Lu-TST001较生理盐水对照组显著抑制肿瘤生长,11.10 MBq组疗效更优。
  • 残留组织的H&E染色和Ki67免疫组化证实治疗后肿瘤组织破坏、肿瘤细胞增殖减少。
  • 高剂量[177Lu]Lu-TST001治疗时心脏、脾、胃等重要器官未见明显短期毒性,无明显血液毒性或肝脏毒性。

临床怎么用

  • 原文结论指出[177Lu]Lu-TST001在临床前研究中具有较强临床转化潜力,为CLDN18.2过表达肿瘤(包括胃癌)提供新的有前景的治疗选择,未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Gastric cancer (GC), one of the most prevalent and deadliest tumors worldwide, is often diagnosed at an advanced stage with limited treatment options and poor prognosis. The development of a CLDN18.2-targeted radioimmunotherapy probe is a potential treatment option for GC. METHODS: The CLDN18.2 antibody TST001 (provided by Transcenta) was conjugated with DOTA and radiolabeled with the radioactive nuclide 177Lu. The specificity and targeting ability were evaluated by cell uptake, imaging and biodistribution experiments. In BGC823CLDN18.2/AGSCLDN18.2 mouse models, the efficacy of [177Lu]Lu-TST001 against CLDN18.2-expressing tumors was demonstrated, and toxicity was evaluated by H&E staining and blood sample testing. RESULTS: [177Lu]Lu-TST001 was labeled with an 99.17%±0.32 radiochemical purity, an 18.50 ± 1.27 MBq/nmol specific activity and a stability of ≥ 94% after 7 days. It exhibited specific and high tumor uptake in CLDN18.2-positive xenografts of GC mouse models. Survival studies in BGC823CLDN18.2 and AGSCLDN18.2 tumor-bearing mouse models indicated that a low dose of 5.55 MBq and a high dose of 11.10 MBq [177Lu]Lu-TST001 significantly inhibited tumor growth compared to the saline control group, with the 11.1 MBq group showing better therapeutic efficacy. Histological staining with hematoxylin and eosin (H&E) and Ki67 immunohistochemistry of residual tissues confirmed tumor tissue destruction and reduced tumor cell proliferation following treatment. H&E showed that there was no significant short-term toxicity observed in the heart, spleen, stomach or other important organs when treated with a high dose of [177Lu]Lu-TST001, and no apparent hematotoxicity or liver toxicity was observed. CONCLUSION: In preclinical studies, [177Lu]Lu-TST001 demonstrated significant antitumor efficacy with acceptable toxicity. It exhibits strong potential for clinical translation, providing a new promising treatment option for CLDN18.2-overexpressing tumors, including GC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zeng Z, Li L, Tao J, et al. [177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models. Eur J Nucl Med Mol Imaging. 2023. PMID: 38062170. doi:10.1007/s00259-023-06561-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。